We were founded in 2007 to discover and develop novel therapeutic solutions leveraging hypoxia inducible factor—or HIF—biology, a primary regulator involved in multiple major biological pathways.
Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor biology. Akebia’s lead product candidate, vadadustat, is an investigational oral therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. Akebia’s global Phase 3 program for vadadustat, which includes the PRO2TECT studies for non-dialysis patients with anemia secondary to chronic kidney disease and the INNO2VATE studies for dialysis-dependent patients, is currently ongoing. For more information, please visit our website at www.akebia.com.
Global leadership in hypoxia inducible factor (HIF) biology. Dedicated to advancing care for serious disease Pursuing advances across multiple disease states.